Connection

Announcement

You can now add alternative names! Click here to add other names that you've published under.

Search Results to Larry Johnson

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Johnson, Larry

One or more keywords matched the following items that are connected to Johnson, Larry

Item Type	Name
Academic Article	Gene therapy for cystic fibrosis using E1-deleted adenovirus: A phase I trial in the nasal cavity
Grant	A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
Grant	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Grant	A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Grant	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation
Grant	A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Cystic Fibrosis
Grant	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Grant	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)
Grant	Cystic Fibrosis: A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 (249908)
Grant	CX-280-202: A Phase 1B Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients with Cystic Fibrosis (IRB 260736)
Grant	A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
Grant	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
Grant	Cystic Fibrosis: A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 (249908)
Grant	A Phase IIa, randomized, double-blind, placebo-controlled study to evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation
Grant	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis
Grant	CX-280-202: A Phase 1B Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety of CB-280 in Patients with Cystic Fibrosis (IRB 260736)
Grant	A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Cystic Fibrosis

Search Criteria

S Phase